Genetic and epigenetic regulation of gene expression in fetal and adult human livers by unknown
Bonder et al. BMC Genomics 2014, 15:860
http://www.biomedcentral.com/1471-2164/15/860RESEARCH ARTICLE Open AccessGenetic and epigenetic regulation of gene
expression in fetal and adult human livers
Marc Jan Bonder1†, Silva Kasela2,3†, Mart Kals2,4, Riin Tamm2,3, Kaie Lokk3, Isabel Barragan5, Wim A Buurman6,
Patrick Deelen1,7, Jan-Willem Greve8, Maxim Ivanov5, Sander S Rensen6, Jana V van Vliet-Ostaptchouk9,10,
Marcel G Wolfs11, Jingyuan Fu1, Marten H Hofker11, Cisca Wijmenga1, Alexandra Zhernakova1,
Magnus Ingelman-Sundberg5, Lude Franke1*† and Lili Milani2*†Abstract
Background: The liver plays a central role in the maintenance of homeostasis and health in general. However,
there is substantial inter-individual variation in hepatic gene expression, and although numerous genetic factors
have been identified, less is known about the epigenetic factors.
Results: By analyzing the methylomes and transcriptomes of 14 fetal and 181 adult livers, we identified 657
differentially methylated genes with adult-specific expression, these genes were enriched for transcription factor
binding sites of HNF1A and HNF4A. We also identified 1,000 genes specific to fetal liver, which were enriched for
GATA1, STAT5A, STAT5B and YY1 binding sites. We saw strong liver-specific effects of single nucleotide polymorphisms
on both methylation levels (28,447 unique CpG sites (meQTL)) and gene expression levels (526 unique genes (eQTL)),
at a false discovery rate (FDR) < 0.05. Of the 526 unique eQTL associated genes, 293 correlated significantly not only
with genetic variation but also with methylation levels. The tissue-specificities of these associations were analyzed in
muscle, subcutaneous adipose tissue and visceral adipose tissue. We observed that meQTL were more stable between
tissues than eQTL and a very strong tissue-specificity for the identified associations between CpG methylation and
gene expression.
Conclusions: Our analyses generated a comprehensive resource of factors involved in the regulation of hepatic gene
expression, and allowed us to estimate the proportion of variation in gene expression that could be attributed to
genetic and epigenetic variation, both crucial to understanding differences in drug response and the etiology of liver
diseases.
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The liver plays a central role in the maintenance of ho-
meostasis and health in general. Given the substantial
inter-individual variation seen in metabolism, regulation
of nutrients, protein synthesis, and detoxification of xe-
nobiotics. It is essential to have a better understanding
on inter-individual variation of gene expression, methy-
lation and genetic effects specific to liver, and on differ-
ent conditions, e.g. developmental stages. These variations* Correspondence: lude@ludesign.nl; lili.milani@ut.ee
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unless otherwise stated.can affect the liver’s metabolic properties, leading to high
levels of metabolites, either in the forms of lipids, proteins
or xenobiotics, which can result in serious diseases or
toxic side-effects. For example, several single nucleotide
polymorphisms (SNPs) associated with liver function and
related diseases have been identified through genome-
wide association (GWA) studies [1-6]. We and others
have studied how these SNPs affect liver gene expres-
sion levels by mapping expression quantitative trait loci
(eQTL) [7-11], and several genetic variants that regulate
genes involved in the absorption, distribution, meta-
bolism and excretion of drugs (ADME genes) have also
been identified.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DNA methylation and histone modifications) also play
an important role in regulating tissue-specific gene ex-
pression [12-14]. In particular, such mechanisms can
influence the expression of hepatic ADME genes. For
example, the methylation status of a CpG island in exon
2 of CYP1A2 was shown to correlate with interindivi-
dual differences in the expression of this gene in human
livers [15]. Given that CYP1A2 is an important drug-
metabolizing enzyme, those factors that influence its epi-
genetic state may also contribute to the individual drug
response. Interestingly, the epigenetic state of ADME
genes, at least in rodent livers, can change in response
to xenobiotic exposure [16,17], thus opening the per-
spective for epigenetics-mediated drug-drug interactions.
More examples on epigenetic regulation of ADME genes
have been reviewed by Kacevska et al. [18]. However, the
majority of such data come from studies of epigenetic al-
terations observed either in tumors, or in cell lines
treated with DNA demethylating agents. So far it is not
clear, to which extent such cancer-related or experimen-
tally induced epigenetic alterations correspond to the
natural epigenetic variability in human livers. Hence, it
is essential to include epigenetic variation when studying
the regulation of hepatic gene expression, to further ex-
plain the causes of differences in drug response and the
etiology of diseases associated with liver function.
Here we present a comprehensive survey of the methy-
lome and transcriptome of the human liver (Figure 1A).
First, we addressed the regulation of gene expression in
the developing human liver by comparing genome-wide
expression and methylation levels in 96 adult and 14 fetal
livers from the Karolinska Liver Bank. Then we used gen-
etic, epigenetic and gene expression data from the adults,
along with an extra cohort of 85 Dutch adult liver samplesFigure 1 Study design and distribution of CpG sites. (A) Study design
*) conservation compared across tissues; #) compared in fetal vs adult liver
between fetal and adult livers. The bar plot shows the percentage of differ
bars) or hypomethylated (grey bars) in fetal livers compared to adult livers
Distribution of differentially expressed and methylated genes depending o
CpG island regions in case of significant increased or decreased gene exprto investigate the regulation of gene expression in the
human liver. Finally, we explored the tissue specificity
of the identified associations between SNPs, methy-
lation and expression in other tissues from the Dutch
adult samples.Results
Developmental regulation of hepatic gene expression
The epigenome of the developing human liver
We first compared the epigenomes of 8- to 21-week-old
fetal livers with adult livers. We assessed the methylation
levels of 366,074 variable CpG sites and found 28,917
CpG sites (annotated to 12,619 unique genes) that showed
a significant difference (absolute mean beta value differ-
ence > 0.2, FDR < 0.05) between fetal and adult liver tissue
(see Supplementary Online Methods in the Additional
files 1 and 2). Although the number of hypomethylated
CpG sites in fetal liver (53.4%) was similar to the number
of hypermethylated sites (46.6%) in this cohort, we ob-
served an age-specific association between the genomic
location of CpG sites and whether they were hypo- or
hypermethylated (chi-squared test p-value < 2.2 × 10−16).
In fetal livers, the majority (86%) of the differentially
methylated CpG sites that are located within CpG islands
(CGI) were hypomethylated, whereas this was not the case
for CpG sites outside CGIs, where roughly 50% of the
CpG sites were either hypo- or hypermethylated in fetal
livers (Figure 1B). This is particularly interesting because
in both adult and fetal livers, close to 80% of the CpG sites
within CGI are not methylated, with > 95% overlap be-
tween the two age groups. Accordingly, the CpG sites
within CGIs that were hypomethylated in the fetal livers
mostly had intermediate methylation levels in the adult
liver samples (Additional file 3).describing the investigated biomaterials and analyses performed.
s. (B) Distribution of the location of differentially methylated CpG sites
entially methylated CpG sites (y-axis) that are hypermethylated (black
in CpG islands, shores, shelves and other regions of the genome. (C)
n the relation to CpG islands. Pie charts illustrating the distribution of
ession and significant hyper- or hypomethylation.
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entially methylated in fetal liver compared to adult liver,
we used the GREAT pathway tool [19]. The CpG sites
that were hypomethylated in the adult livers and hy-
permethylated in fetal liver were strongly enriched for
metabolic pathways, such as the steroid metabolic process
the regulation of lipid metabolic processes, regulation of
generation of precursor metabolites and energy, and re-
gulation of glycolysis (all with p-values < 1.15 × 10−44)
(Table 1A). However, the genes that were associated with
hypomethylated CpG sites in the fetal samples were
strongly enriched for pathways of insulin receptor sig-
naling, regulation of glycogen synthase activity, differenti-
ation processes, and developmental functions (Table 1B).
The transcriptome of the developing liver
Comparison of gene expression levels between the fetal
and adult liver samples yielded 3,284 differentially ex-
pressed probes (absolute log2-fold change > 1.0, FDR <
0.05, Additional file 4). Pathway analysis, using Gene
Network [20], confirmed that 1,396 genes with higher
expression in the adult livers were strongly enriched for
metabolic functions like monocarboxylic acid, steroidTable 1 Gene Ontology analysis of differentially methylated g
A. Top 10 biological processes associated with hypomethylated genes
Term Name
Steroid metabolic process
Regulation of lipid metabolic process
Regulation of generation of precursor metabolites and energy
Regulation of glycolysis
Sterol metabolic process
Positive regulation of lipid metabolic process
Regulation of cellular carbohydrate catabolic process
Regulation of lipid transport
Cholesterol metabolic process
Regulation of cellular ketone metabolic process
B. Top 10 biological processes associated with hypomethylated genes
Term Name
Insulin receptor signalling pathway
Positive regulation of glycogen (starch) synthase activity
Anterior/posterior pattern specification
Regulation of gene expression by genetic imprinting
Regulation of glycogen (starch) synthase activity
Genetic imprinting
Response to estrogen stimulus
Positive regulation of insulin receptor signalling pathway
Positive regulation of cell cycle
Luteinizing hormone secretion
1Fold enrichment - fold enrichment of number of genomic regions in the test set w
2Observed region hits - actual number of genomic regions in the test set with the aand bile acid metabolic processes, as well as the response
to xenobiotic process (Table 2A). In contrast, 1,277 genes
that were highly expressed in fetal tissue were associated
with regulating organelle organization, chromosome or-
ganization, and tetrapyrrole (e.g. hemoglobin) biosynthetic
processes (Table 2B). These observations are in line with
the fetal development, which is characterized by tis-
sue differentiation and growth and by the fact that the
liver is predominantly a hematopoietic organ during this
period [21].
Orchestration of epigenetics and transcriptomics in
regulating liver development
We found 1,655 genes that showed both differential ex-
pression and differential methylation in adult vs. fetal
livers (Additional file 5). More specifically, 657 genes
were linked to probes with higher expression levels in
adults, and 1,000 genes linked to probes that were more
highly expressed in fetal livers (with an overlap of two
genes). As expected, these genes are even more signifi-
cantly enriched for developmental stage-specific functions,
such as drug response for the adult cohort (p-value 4.0 ×
10−131) and liver development for the fetal cohort (p-valueenes in fetal versus adult livers
in adult livers

























Table 2 Gene Ontology analysis of differentially
expressed genes in fetal versus adult liver
A. Top 10 biological processes associated with hyperexpressed
genes in adult livers
Term P-value Nr of
genes
Monocarboxylic acid metabolic process 2.80E-205 347
Lipid localization 8.26E-202 201
Lipid transport 1.99E-197 180
Steroid metabolic process 2.91E-196 257
Bile acid metabolic process 1.13E-192 40
Response to xenobiotic stimulus 9.88E-184 114
Cellular response to xenobiotic stimulus 9.88E-184 114
Xenobiotic metabolic process 6.72E-183 113
Bile acid biosynthetic process 6.23E-178 23
Response to glucocorticoid stimulus 2.61E-173 131
B. Top 10 biological processes associated with hyperexpressed
genes in fetal livers
Term P-value Nr of
genes
Negative regulation of organelle organization 3.93E-162 138
Regulation of organelle organization 1.73E-132 370
Negative regulation of cellular component
organization
3.40E-127 265




Tetrapyrrole biosynthetic process 1.84E-112 34
Negative regulation of chromosome organization 6.05E-108 29
Chromatin assembly or disassembly 8.76E-106 128
Pigment biosynthetic process 1.73E-103 53
G1 phase 6.25E-102 36
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http://www.biomedcentral.com/1471-2164/15/8606.0 × 10−90). In the majority of the genes with more than
one detection probe, the differences in expression levels
were very similar between fetal and adult livers. However,
in two genes (TGM2 and INS-IGF2), one of the probes
was more highly expressed in fetal livers, while the other
probe reflected higher expression in adult livers. The lo-
cation of the differentially methylated CpG sites differed
significantly in relation to CGIs, depending on the expres-
sion and methylation differences between fetal and adult
livers (chi-squared test p-value < 2.2 × 10−16, Figure 1C):
for genes with a lower expression in fetal livers, the hypo-
methylated CpG sites more often map within CpG islands,
shores and shelves, while the hypermethylated CpG sites
map further away from CGI regions.
Regions within 2 kb of the transcription start site (TSS)
of the 1,655 genes are enriched for binding sequences
of transcription factors essential for the development
or function of the liver, specifically HNF4A (adjusted
p-value = 2 × 10−73) and HNF1A (adj. p-value = 6 × 10−38);hematopoietic transcription factors GATA1 (adj. p-value =
8 × 10−36), STAT5A (adj. p-value = 2 × 10−43), and STAT5B
(adj. p-value = 1 × 10−49); and YY1 (adj. p-value = 2 ×
10−36), which plays a fundamental role in embryogenesis
and differentiation. We therefore investigated the expres-
sion levels of these transcription factors and observed that
transcripts for the HNF1A and HNF4A genes were more
highly expressed in adult livers, and GATA1, STAT5A,
STAT5B and YY1 were all more highly expressed in fetal
livers (Figure 2, Additional file 6).
Table 3 lists the 20 genes with the largest differences
in expression and methylation, clearly illustrating the
fetal-specific expression of genes involved in differenti-
ation and hematopoiesis (e.g. DLK1, HBZ, HBM, AHSP,
EPB42 and NFE2), and the adult-specific expression of
genes involved in drug metabolism, catabolism and other
biosynthesis processes. CYP2E1 and CYP2C8 are the cy-
tochrome P450 (CYP) genes; these show the most sig-
nificant difference in expression levels between fetal and
adult liver, with an approximately 7-fold higher expres-
sion level in adult liver.
Genetic and epigenetic effects on inter-individual variability
in gene expression
Correlation in DNA methylation and gene expression
We next assessed whether DNA methylation is corre-
lated to gene expression levels in the adult samples. We
combined data from the Karolinska Liver Bank and Dutch
liver samples (total number of samples with expression
and methylation data = 158) and compared expression
probes with CpG sites that map within 250 kb of these
probes. We did not include the fetal samples due to the
large developmental differences reported above, and we
estimated that the fetal samples would not add any
considerable statistical power for the analyses. We identi-
fied 3,238 significant methylation-expression associations
(eQTMs, Additional file 7), comprising 1,988 unique
expression probes (in 1,798 genes) and 2,980 CpG sites
(reflecting 2,057 unique genes), with a permutation p-
value < 0.05. As expected, there are more eQTMs with a
negative correlation between expression levels and CpG
methylation levels (58.4%), irrespective of the CpG site
location in relation to CpG islands. Furthermore, for
CpG sites with strong correlation between expression
and methylation levels, and/or within 50 kb of the ex-
pression probes, we observed an overrepresentation of
negative correlations (chi-squared test p-value < 2.2 ×
10−16, Figure 3).
Regulation of gene expression by genetic polymorphisms
We next explored the effects of genetic variation on liver
gene expression levels. Expression quantitative trait locus
(eQTL) mapping in the adult livers (meta-analysis of
the two cohorts, combined number of samples with
Figure 2 Expression levels of transcription factors in fetal and adult livers. Box plots of the log2 transformed expression levels (y-axis) are
shown for the adult and fetal liver samples (x-axis). The transcripts for HNF1A and HNF4A were expressed at significantly higher levels in the adult
livers, while YY1, GATA1, STAT5A and STAT5B were expressed at higher levels in the fetal livers.
Table 3 Top 20 genes with largest difference in expression and differential methylation between fetal and adult livers
Gene Median expression logFC Adj p-value
(FDR)
Mean beta value Beta value
difference
Adj p-value
(FDR)Adult Fetal Adult Fetal
DLK1 3.27 12.64 9.15 3.55E-46 0.42 0.63 0.22 3.19E-36
HBZ 3.23 12.35 9.07 1.82E-45 0.8 0.55 −0.25 4.02E-18
HBM 3.01 12.52 9.03 4.27E-42 0.42 0.21 −0.21 2.55E-11
AHSP 4.37 13.26 8.46 2.66E-42 0.74 0.41 −0.33 1.43E-34
EPB42 3.13 11.25 8.19 2.26E-48 0.89 0.47 −0.42 3.84E-64
CYP2E1 13.42 4.1 −7.64 8.63E-36 0.51 0.88 0.36 1.10E-41
HBE1 2.87 10.66 7.63 4.10E-48 0.76 0.49 −0.27 1.41E-34
CRP 13.33 4.33 −7.27 7.71E-34 0.53 0.89 0.36 2.99E-42
C9 11.91 3.59 −7.18 3.98E-39 0.48 0.84 0.36 8.73E-39
APCS 12.69 4.39 −7 5.95E-40 0.45 0.88 0.43 7.26E-48
SLC4A1 4.04 11.3 6.96 1.46E-61 0.75 0.4 −0.35 2.14E-42
NNMT 11.06 3.44 −6.88 4.10E-40 0.36 0.84 0.48 7.10E-45
CYP2C8 12.9 4.83 −6.85 3.42E-31 0.59 0.88 0.29 2.57E-36
AQP9 11.51 3.47 −6.81 1.26E-33 0.39 0.84 0.45 8.23E-45
NFE2 4.1 11.03 6.8 2.29E-47 0.82 0.45 −0.36 3.02E-41
ADH1C 11.93 3.92 −6.69 1.96E-24 0.42 0.81 0.39 8.06E-38
MYL4 3.88 10.77 6.65 6.78E-60 0.88 0.4 −0.48 1.90E-62
C3P1 11.36 3.81 −6.63 2.34E-37 0.73 0.24 −0.49 1.56E-47
RHAG 3.35 10.22 6.56 1.50E-46 0.81 0.49 −0.31 1.64E-47
HSD17B6 12.12 4.61 −6.31 4.88E-29 0.89 0.66 −0.22 1.48E-41
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Figure 3 Distribution of the direction of the expression and methylation correlation coefficient. (A) Proportion of eQTM effects (y-axis)
grouped by the absolute Spearman correlation coefficient. Grey and black colors represent negative and positive correlation between expression
probe and methylation CpG site, respectively. (B) Proportion of eQTM effects (y-axis) grouped by the distance between expression probe and
CpG site in kilobase pair (kb). Grey and black colors represent negative and positive correlation between expression probe and methylation CpG
site, respectively.
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47,168 significant SNP-probe pair correlations (FDR < 0.05),
representing 751 unique genes (Additional file 8). The
eQTL probes are significantly enriched for liver-specific
genes (area under the curve (AUC) 0.67, p-value 4 × 10−57,
as reported by Gene Network) and are strongly enriched
for genes encoding drug-metabolizing enzymes (p-value
2.0 × 10−19). We compared our results with reported liver
cis-eQTLs [7-10,22] and observed that we could replicate
667 reported eQTL genes, however we also identified 84
new eQTL genes (Additional file 8).
Influence of genetic variation on DNA methylation
We investigated the effects of SNPs on CpG methylation
(meQTL) in adult liver samples (meta-analysis, com-
bined number of samples with methylation and genotype
data =161). In total we found significant cis-meQTL for
28,447 unique methylation probes (FDR < 0.05, mapping
to 12,054 unique genes), reflecting 1,477,126 different
SNP-CpG site combinations. In contrast to the eQTL,
we did not observe any enrichment of liver functions for
these 12,054 meQTL associated genes. Looking further
into the SNPs affecting DNA methylation and gene ex-
pression, we identified 215 unique genes and 10,432
unique SNPs associated with both an eQTL and meQTL,
resulting in a total of 30,644 overlapping QTL effects.
Interestingly, for most of the 215 genes (69.3%) influ-
enced by both an eQTL and meQTL we observed an
opposite effect direction, i.e. the same genotype was
associated with higher methylation levels and lower ex-
pression levels, or vice versa (Additional file 9). This effect
is strongest in the CpG islands and CpG island shores,
where it occurs in more than 75% of the cases (Additional
file 10).Contribution of genetic variants and DNA methylation to
variation in hepatic gene expression
Once we had identified eQTL and eQTMs, we ascer-
tained to what extent SNPs and DNA methylation could
jointly explain the variation in liver gene expression le-
vels. We selected 293 expression probes (reflecting 274
unique genes) that had both a significant cis-eQTL and
significant eQTM effect. We then tested four different
linear models (see Supplementary Online Methods in
the Additional file 1) to assess the proportion of vari-
ation in gene expression that could be explained. For
83% of these 293 expression probes, most of the expres-
sion variation was explained by a SNP (Additional file 11),
whereas for the remaining 17% the expression vari-
ation was most strongly explained by a specific CpG site.
For the latter cases, we observed that these expression-
associated CpG sites were likely to have a meQTL effect
(chi-squared p-value = 0.035). As expected, when we com-
bined the SNP genotype and CpG site methylation levels,
we could explain more of the expression variation than by
using either SNP or methylation levels alone. Given the
correlations between genotypes and methylation levels, we
also estimated the unique contributions of the two on
gene expression levels (Additional file 12). Overall, SNP
genotypes uniquely explain a greater proportion of the
variation in gene expression (median 0.1, standard de-
viation 0.122) than methylation levels (median 0.029,
standard deviation 0.049). The SNPs and CpG sites with
particularly high correlations with the expression levels
were generally closer to the transcription start site of the
corresponding genes (Additional file 13).
The contributions of SNPs and DNA methylation
levels to the proportion of variation explained in gene
expression levels are illustrated in Additional file 14 and
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http://www.biomedcentral.com/1471-2164/15/860Table 4 by 16 unique ADME genes that had both sig-
nificant eQTL and eQTMs. The ADME gene list was ex-
tracted from http://www.pharmaADME.org. For the GSTT1,
GSTM1, UGT1A1, GST01 and PON1 genes, DNA me-
thylation explains a larger proportion of the variation in gene
expression levels compared to SNP genotypes. Overall,
we found that adding more CpGs to the model, which
were all associated to the selected expression probes of
the same gene, did not significantly increase the power
to explain more of the variation in gene expression
(p-value < 2.2 × 10−16). In addition to the ADME genes,
we also investigated the role of SNPs and CpG site methy-
lation in the regulation of genes associated with diseases
and liver function by querying all SNPs from the GWAS
catalog (http://www.genome.gov/gwastudies/) in our list
of identified eQTLs. We identified cis-acting SNPs and
DNA methylation differences that were associated with
the expression of 47 genes previously identified in differ-
ent GWA studies with complex traits, including enzyme
and metabolite levels as well as cardiovascular and inflam-
matory bowel diseases (Additional file 15).
Tissue-specificity of eQTL, meQTL and eQTMs
Since we had also generated methylation and expression
data for three other tissues (muscle, subcutaneous- (SAT)
and visceral adipose tissue (VAT)) from the same indi-
viduals in the Dutch cohort, we could assess the tissue-Table 4 Proportion of explained variation by SNPs and CpG s
Gene/Locus Chr SNP CpG site
SNP onl
GSTT1 22 rs9612520 cg05380919 50%
CYP3A5 7 CS015290 cg03133378 55%
GSTM1 1 rs75953876 cg18938907 11%
GPX7 1 rs11810754 cg11953272 48%
UGT1A1 2 rs7592624 cg11811840 22%
SLC22A18 11 rs413781 cg24724917 30%
FMO4 1 rs2223477 cg14981176 39%
GSTM3 1 rs115636764 cg23645476 21%
SLC19A1 21 rs7867 cg27210852 22%
GSTO2 10 rs11595547 cg23659134 20%
PON1 7 rs854533 cg07404485 13%
DHRS2 14 rs57350570 cg07125017 23%
GSTA4 6 rs538920 cg22486834 14%
CEBPA 19 rs80241821 cg19035908 17%
MGST3 1 rs10737515 cg16553119 12%
DHRS7 14 rs376391 cg18906360 12%
*F-test p-value < 0.05; **F-test p-value < 0.005.
F-test null hypothesis: model for gene expression with the SNP and CpG site as exp
sites1 fit equally well with the differences being due to random chance.
SNP and all CpG sites1 - the CpG sites that have eQTM effects with the expression pspecificity of the detected eQTL, meQTL and eQTM ef-
fects. We had previously compared liver eQTL with other
tissues for only a limited number of samples [11], so we
re-did this analysis with the new adult liver samples from
the Karolinska Liver Bank. For liver eQTL, approximately
40-50% of the effects found in one tissue could also be sig-
nificantly detected in another tissue (Figure 4A). We iden-
tified only a few opposite allelic effects (<1%) between the
tissues (Additional file 16A and B), suggesting that if a
SNP affects expression in multiple tissues, the allelic dir-
ection is mostly identical. The eQTL effects (n = 32,863)
that were only present in liver and not in the other three
tissues were related to genes strongly specific to liver func-
tion (p-value 5 × 10−53) and metabolic and catabolic pro-
cesses (p-values < 5 × 10−20).
Contrary to the strong tissue-specificity of eQTL,
meQTL were much more stable across the different tis-
sues. On average, 70% of the meQTL are shared between
at least two tissues, with over 98% of their effects having
the same allelic direction (Figure 4B, Additional file 16C
& D). As we had observed for eQTL, there were also a few
significant meQTL that showed an opposite allelic direc-
tion between liver and the other three tissues (Additional
file 17). The CpG sites of the meQTL with opposite effects
were more often located outside the gene bodies (p-value
1.53 × 10−11), but when they were in gene bodies, they
were in exons rather than introns (p-value 1.7 × 10−90).ites associated with the expression of ADME genes
% of variation in expression explained by

















lanatory variables and model for gene expression with the SNP and all CpG
robe.
Figure 4 Venn diagram of the overlap of QTLs in four
tested tissues. The number of overlapping (A) eQTL, (B)
meQTLs, (C) eQTMs in shown for adult human liver, VAT, SAT
and muscle samples.
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for the identified eQTMs. Only up to 4% of the eQTMs
found in one tissue were also detectable with an identical
effect direction in another tissue (Figure 4C, Additional
file 16E).Genes with adult-specific functions are enriched for eQTL
We hypothesized that the expression of genes with im-
portant functions in the adult liver should be under
strict genetic and epigenetic control. We thus focused
on the set of probes with significantly higher and lower
expression levels in adult liver compared to fetal liver
(from the previous section “The transcriptome of the de-
veloping liver”), and formed a matched set of probes that
were not differentially expressed between the two groups
but displayed similar median expression levels and stan-
dard deviations in the adult liver samples. We observed
that the expression of these adult liver-specific probes
are much more likely to be affected by SNPs than the
matched set of probes (1.43 times more than expected,
chi-squared test p-value = 8.8 × 10−7). Furthermore, we
observed that these probes were 1.24-fold enriched for
liver-specific eQTL probes compared to a matched set
of probes with eQTL in multiple tissues (chi-squared test
p-value = 8.847 × 10−6). Vice versa, probes with lower ex-
pression levels in adult liver compared to fetal liver did
not differ from the matched set of probes in terms of hav-
ing eQTL and liver-specific eQTL effects. Furthermore,
we did not observe any enrichment of meQTL in the adult
liver-specific methylation probes.Discussion
Previous studies on the regulation of gene expression in
human liver have only accounted for the effect of genetic
variation in adult samples [7-11]. In this study, we inves-
tigated the developmental regulation of gene expression
in human livers by comparing the expression and me-
thylation levels of genes in adult and fetal livers. In addi-
tion, we used both genetic variants and DNA methylation
differences in order to explain the variability in transcript
levels observed in adult livers. Comparison of the fetal and
adult liver methylomes and transcriptomes revealed that
hypomethylated CpG sites and up-regulated genes were
closely related to the tissue-specific functions: with fetal
livers enriched for developmental and hematopoietic func-
tions, while catabolic and metabolic processes were more
prominent in adult livers. This has been described in the
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ment in mice [23-25].
As the differences in methylation between fetal and
adult livers were very large, when attempting to charac-
terize the effects of variable methylation on gene expres-
sion levels in adults, we performed the eQTM analysis
using a panel of only adult liver samples. Similarly to
Gutierrez-Arcelus et al. [26], we observed both positive
and negative correlations between DNA methylation and
gene expression across the samples, with similar distri-
butions across different genomic regions. Bell et al. have
also observed a modest but significant excess of negative
correlations between DNA methylation and variation in
gene expression levels across individuals [27]. It has
been reported that the role of DNA methylation appears
to depend on the genomic context [28]: for example,
CpG sites located near the genes and/or with a stronger
correlation between the methylation and expression were
more likely to display a negative correlation. Interestingly,
CpG sites downstream of the expression probes displayed
less negative correlations than those upstream of the
probes, indicating that methylation in gene bodies is as-
sociated with active gene expression, as known from the
early days of DNA methylation research [29,30]. This
paradox – in which methylation in the promoter is nega-
tively correlated with the expression, whereas methylation
in the gene body is positively correlated with expression
[30] – can be explained by the fact that, in mammals,
DNA methylation silences the initiation of transcription,
but not transcription elongation [28].
Our eQTL mapping in adult livers revealed 751 unique
genes, which were strongly liver-specific and enriched for
drug metabolizing functions. Of these, 84 genes were new
associations, while others have already been reported
[7-10,22]. The new associations are probably due to the
larger number of samples and imputation of SNPs not
present on previously used genotyping arrays, using data
from the 1000 Genomes project. While we observed liver-
specific associations with eQTL, the meQTL were not
enriched for liver-specific functions. Furthermore, when
we analyzed the SNPs that had significant effects on both
methylation and expression, in most of the genes the same
SNP allele had an opposite effect on gene expression com-
pared to the methylation level, and this effect was most
evident in CpG islands and shores (Additional file 10).
These results show that, although there are many asso-
ciations between SNPs and methylation levels, the rela-
tionships between them are not clear and do not reflect
tissue-specific functions.
Inter-individual variability in ADME gene expression
has been shown to affect drug efficacy, toxicity, and sus-
ceptibility to environmental toxins [31]. When we focused
on the expression of ADME genes, we observed very
strong cis-acting SNP and DNA methylation effects for 16genes (Table 4), including members of the glutathione
S-transferases (GSTs) family of phase II ADME iso-
zymes: GSTA4, GSTM1, GSTM3, GSTO2 and GSTT1;
solute carrier transporters SLC19A1 and SLC22A18, re-
sponsible for the transmembrane transfer of multiple
drugs and endogenous compounds; and FMO4, GPX7,
PON1 and UGT1A1. GSTT1 is involved in the conjuga-
tion of a variety of compounds [32-35], while GSTM1
functions in the detoxification of exogenous/endoge-
nous toxins. The effects of epigenetic modifications on
the expression of these genes have been reported in
blood and brain tissues [36,37]. In our study, we ob-
served that both SNPs and DNA methylation contribute
to the variability of the expression of these genes. For
example, the SNP rs2739330, downstream of the GSTT1
gene and upstream of the DDT gene, has been reported
to be associated with gamma-glutamyl transferase levels
in plasma [38]. This SNP, together with methylation
levels of a nearby CpG site cg05380919, explains 78% of
the variability in the expression of GSTT1, possibly with
a stronger contribution from the methylation levels of
the CpG site. Similarly, for GSTM1 the strongest SNP
only explains 11% of the variation in its expression,
while methylation levels of the CpG site cg18938907
has a much stronger association with the expression of
the gene, and may be responsible for up to 55% of the
variation (Additional file 11). The CpG site falls within a
CpG island that spans the promoter and a portion of
the gene’s first intron. Interestingly, they are located
near the transcription factor binding site of TBP, which
has been shown to bind to the promoter of GSTM1 in
HepG2 cells, according to ENCODE ChIP-Seq data.
A substantial portion of the overall phenotypic variance
in hepatic enzyme PON1 activity between individuals re-
mains unexplained. Besides a variety of non-genetic fac-
tors, numerous transcription factors [39] and miRNA
regulation [40], various functional PON1 polymorphisms
have been shown to influence serum PON1 levels and ac-
tivity [39,41]. The SNP rs705379 has been shown to be as-
sociated with approximately 50% mean reductions in
serum PON1 protein levels as well as transcript levels
[41,42]. In our study, it was interesting to see that this
SNP was associated with increased methylation of nine
CpG sites in its vicinity and with a lower expression of
PON1.
Glutathione peroxidases (GPX) constitute a major an-
tioxidative damage enzyme family [43] and are thus im-
portant in cancer therapy [44]. Not only genetic but also
epigenetic mechanisms of gene regulation have been pro-
posed for GPX7, while recently a CpG island was identi-
fied as a key player in regulating GPX7 expression [45].
In total, we identified 87 SNPs in the GPX7 gene affect-
ing the methylation of nine CpG sites (meQTL), with
six of the sites being directly implicated in quantitative
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cated the two eQTL reported in human liver samples
for GPX7 [10], and for the first time identified their as-
sociation with differences in methylation of CpG sites,
which are further correlated with changes in GPX7 ex-
pression levels. One of the expression-associated SNPs
discovered in this study, rs11810754, appears to explain
most of the variation in the expression levels of the
gene (48%), while the CpG site with the strongest cor-
relation with expression (cg11953272) did not add any
extra information to the variability of the expression of
the gene (only 1%, Table 4).
Three other tissues (muscle, SAT, VAT) were used to
assess the tissue-specificity of both eQTL and meQTL
effects. Our eQTL results showed that over half of the
associations of SNPs with expression in one tissue could
not be detected in another tissue (with identical eQTL
allelic effect directions). This is similar to other studies
[7,9,11]. In contrast, SNP-methylation correlations were
much less tissue-specific than SNP-expression correl-
ation: approximately 70% of the meQTL were also iden-
tified in any of the other tissues. To the best of our
knowledge, this has not been described before, but could
be due to sequence-dependent DNA methylation or the
fact that genetic variation in a similarly methylated region
can affect the entire region (given that we have excluded
the direct effects of SNPs on methylation probes). On the
other hand, we observed that DNA methylation associated
with expression levels (i.e. eQTMs) are highly tissue-
specific, in accordance with the fact that DNA methy-
lation plays an important role in regulating tissue-specific
gene expression. Thus, conclusions drawn from eQTL or
eQTM data in one tissue cannot be extrapolated to other
tissues, whereas the effect of SNPs on methylation is more
likely to be detectable in an alternative tissue, for example
DNA in blood, which is more readily accessible.
The greatest limitation of our study was the use of mi-
croarrays instead of massively parallel sequencing. Des-
pite stringent filtering and remapping of expression and
methylation probe sequences, we cannot rule out all tech-
nical artefacts inherent to microarray studies. Another
drawback of microarrays is also their lower coverage of
the genome, with the expression arrays only covering a
few exons per gene, and the methylation array containing
approximately 1% of the CpG sites in the human genome.
Future studies using RNA and genome sequencing should
be able to generate a more complete picture of the factors
involved in the regulation of gene expression in human
liver or other tissues.
Conclusions
By performing a genome-wide survey of genomic and epi-
genomic variation and their associations with gene expres-
sion in fetal and adult human liver, we have generated acomprehensive resource for the analysis of factors in-
volved in the regulation of hepatic gene expression. The
investigation of fetal livers allowed us to explore the de-
velopmental changes in the hepatic methylome and
transcriptome. Although the role of DNA methylation
in different regions of the genome is still unclear, our re-
sults elucidate the coordinated effects of SNPs and methy-
lation, as well as the tissue specificity of their effects on
gene expression. This strengthens the hypothesis that
knowledge of inter-individual variability, driven by genetic
polymorphisms and DNA methylation marks and their
interaction, is crucial for understanding the causes of dif-
ferences in drug response and the etiology of diseases as-
sociated with liver function.Methods
The materials and methods of this study are described
in detail in the Supplementary Online Methods in the
Additional file 1. Briefly, our study was performed on
two different cohorts, 14 fetal and 96 adult liver sam-
ples from the Karolinska Liver Bank cohort [46,47], and
85 adult samples from the Dutch tissue cohort MORE
(BBMRI obesity cohort) [11,48]. For both datasets, the
number of samples for which there is full expression,
methylation and genotype data is not 100%. We therefore
report the number of samples per specific analysis. DNA
from the samples were genotyped using HumanOmni
BeadChips (Illumina), according to the manufacturer’s in-
structions. We imputed both datasets using the GIANT
release from the 1000 Genomes project, resulting in
5,763,069 unique SNPs, which were used in all our down-
stream analyses. Gene expression data was generated
using HumanHT-12 BeadChips (Illumina), according to
the standard protocol. Bisulfite-converted DNA samples
were hybridized to Infinium HumanMethylation450 Bead-
Chips (Illumina), following the Illumina Infinium HD
Methylation protocol.Availability of supporting data
The data sets supporting the results of this article are
available in the GEO repository, Dutch BBMRI more ex-
pression data: GSE22070; methylation data: GSE61454;
Karolinska expression and methylation data: GSE61279.Additional files
Additional file 1: Supplementary materials & methods. Detailed
descriptions of the samples and methods used; information about
pre-processing, QTL mapping, eQTM analysis, explained variation
analysis etc.
Additional file 2: Differentially methylated genes between fetal and
adult livers. A table listing the 28,917 significant CpG sites which are
differentially methylated when comparing the methylation patterns of
the adult liver with the fetal liver.
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http://www.biomedcentral.com/1471-2164/15/860Additional file 3: Average DNA methylation levels of all CpG sites
on the 450K beadchip and of differentially methylated CpG sites
between adult and fetal livers. Proportion of CpG sites in (A) fetal livers
and (B) adult livers with average beta-values between 0–0.25 and
0.25-0.75 and 0.75-1 grouped by CpG island regions in three different
groups based on the non-significant or significant differential methylation
between fetal and adult livers.
Additional file 4: Differentially expressed genes between fetal and
adult liver. A table listing the 3,284 expression probes which show
significant differential expression when comparing the adult liver with
the fetal liver.
Additional file 5: Differentially expressed and differentially
methylated genes between fetal and adult livers. A table listing the
1,655 genes which are both differentially expressed and differentially
methylated when comparing the fetal liver with adult liver. For every
gene the direction of significant expression and methylation change in
fetal compared to adult liver is given.
Additional file 6: Comparison of the expression levels of
transcription factors in fetal and adult livers. A table listing the
comparison of gene expression levels of transcription factors which are
bioinformatically predicted to influence genes that are differentially
expressed between adult and fetal livers.
Additional file 7: eQTMs identified in liver at FDR 0.05. Information
on the CpG probe, expression probe and details including significance of
the effects is given in this table.
Additional file 8: eQTL identified in liver at FDR 0.05. Information on
the expression probe, SNP and details including significance of the
effects is given in this table.
Additional file 9: Top 15,000 meQTL identified in liver. Information
on the methylation probe, SNP and details including significance of the
effects is given in this table. Full table available upon request (too large
to upload).
Additional file 10: Distribution of opposite and identical effects of
a SNP on gene expression and gene methylation. Proportion of
genes with eQTL and meQTL depending on the effect of the SNP allele
on gene expression compared to the methylation level grouped by CpG
island regions.
Additional file 11: The contributions of SNPs and DNA methylation
levels to the proportion of variation explained in gene expression
levels. A table listing the genes by the proportion of the explained
variation in gene expression by either a SNP (eQTL), a CpG site (eQTM),
both a SNP and a CpG site (eQTL+eQTM) or a SNP and CpG sites
(eQTL+eQTMs).
Additional file 12: Unique proportion of gene expression variation
explained by a SNP or a CpG site. The figure outlines the expression
variation explained uniquely by a SNP (x-axis) vs the variation explained
uniquely by a CpG site (y-axis). In general the SNPs explain more gene
expression variation vs. a single CpG site, however there are some
exceptions.
Additional file 13: Relation between the distance from TSS and the
explained variation in gene expression by a CpG site and a SNP.
Percentage of explained variation in gene expression by a CpG site or a
SNP (y-axis) depending on the distance from the transcription start site of
the corresponding genes (x-axis).
Additional file 14: The contributions of SNPs and DNA methylation
levels to the proportion of variation explained in gene expression
levels of 16 ADME genes. Percentage of explained variation in gene
expression of 16 ADME genes by a SNP (eQTL), a CpG (eQTM), both a
SNP and a CpG site (eQTL+eQTM) or a SNP and CpG sites (eQTL+eQTMs).
Additional file 15: The contributions of SNPs and DNA methylation
levels to the proportion of variation explained in gene expression
levels of genes previously identified in GWA studies. A table listing
the genes by the amount of the explained variation in expression of
genes identified in GWA studies by either a SNP (eQTL), a CpG (eQTM),
both a SNP and a CpG site (eQTL+eQTM) or a SNP and CpG sites
(eQTL+eQTMs).Additional file 16: Overlapping eQTL and meQTL with the same or
opposite allelic direction and eQTMs with consistent direction
identified in multiple tissues.
Additional file 17: meQTL with an opposite allelic direction
between liver and the other three tissues. Illustration of a meQTL
giving an opposite allelic effect in liver as compared to SAT, VAT
and muscle. The C-allele of rs9768559 is associated with decreased
methylation levels at a CpG site (cg07883117) in both the liver sample
sets, while in SAT, VAT and muscle the same allele is associated with
increased methylation levels at the same CpG site.
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